Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Int.biotech. (IBT) Share News

IN BRIEF: International Biotechnology NAV gets Pfizer-Biohaven boost

11th May 2022 17:46

International Biotechnology Trust PLC - London-based investment trust managed by SV Health Managers LLP - Says Pfizer Inc's acquisition of its investee Biohaven Pharmaceutical Holding Co Ltd has boosted net asset value by 3.6%. Pfizer on Tuesday announced the acquisition of Biohaven for USD148.50 per share, at a 74% premium to the price of Biohaven before the announcement. IBT on Tuesday owned 182,000 shares in Biohaven, which constituted around 5.2% of its NAV. Read More

Pfizer's USD12 billion deal for Biohaven could jump-start sector M&A

10th May 2022 18:12

(Alliance News) - Pfizer Inc's move to acquire migraine therapy maker Biohaven Pharmaceutical Holding Co Ltd could spark a wave of M&A sector activity as drugmakers sit on large piles of cash. Read More

IN BRIEF: International Biotechnology notes Pfizer buys investee

10th May 2022 15:27

International Biotechnology Trust PLC - London-based investment trust managed by SV Health Managers LLP - Notes it has stake in Biohaven Pharmaceutical Holding Co Ltd, a pharmaceutical firm which Pfizer Inc has agreed to acquire for USD11.6 billion. Biohaven is International Biotechnology's seventh-largest holding, representing 4.1% of its net asset value as of March 31. International Biotechnology co-manager Ailsa Craig says deal represents sign "Covid cash" is being put to use on M&A in pharmaceutical sector. The trust notes Biohaven is not a constituent of its benchmark Nasdaq Biotech Index. Biohaven is listed on the New York Stock Exchange. Read More

IN BRIEF: International Biotechnology Trust corrects interim return

6th May 2022 12:13

International Biotechnology Trust PLC - London-based investment trust managed by SV Health Managers LLP - Company corrects that, for the six months that ended February 28, its net asset value per share total return was negative 15%, rather than the 13% reported on Wednesday, while the company's benchmark, the Nasdaq Biotechnology Index, returned negative 23%. The correction to the return relates to dividends paid. The trust swung to a pretax loss of GBP48.5 million in the six months from a profit of GBP19.1 million a year previous. International Biotechnology Trust makes a GBP46.5 million loss on investments, versus a gain of GBP20.4 million a year before. NAV per share stands at 648.82 pence at February 28, down from 775.73p a year previous. Says the biotechnology sector has experienced a "significant" period of weakness, but the company's outlook remains positive. Read More

FTSE 100 Latest

Value10,634.31

Change30.83